140 related articles for article (PubMed ID: 32898697)
1. Synthesis and biological evaluation of diaryl urea derivatives as FLT3 inhibitors.
Zhang Q; Zhao K; Zhang L; Jiao X; Zhang Y; Tang C
Bioorg Med Chem Lett; 2020 Dec; 30(23):127525. PubMed ID: 32898697
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
Dokla EME; Abdel-Aziz AK; Milik SN; McPhillie MJ; Minucci S; Abouzid KAM
Bioorg Med Chem; 2022 Feb; 56():116596. PubMed ID: 35033885
[TBL] [Abstract][Full Text] [Related]
3. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 Mar; 12():19. PubMed ID: 23497317
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the selective and efficacious inhibitors of FLT3 mutations.
Zhi Y; Li B; Yao C; Li H; Chen P; Bao J; Qin T; Wang Y; Lu T; Lu S
Eur J Med Chem; 2018 Jul; 155():303-315. PubMed ID: 29894944
[TBL] [Abstract][Full Text] [Related]
5. Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Lin WH; Hsieh SY; Yen SC; Chen CT; Yeh TK; Hsu T; Lu CT; Chen CP; Chen CW; Chou LH; Huang YL; Cheng AH; Chang YI; Tseng YJ; Yen KR; Chao YS; Hsu JT; Jiaang WT
Bioorg Med Chem; 2011 Jul; 19(14):4173-82. PubMed ID: 21708468
[TBL] [Abstract][Full Text] [Related]
6. A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.
Sellmer A; Pilsl B; Beyer M; Pongratz H; Wirth L; Elz S; Dove S; Henninger SJ; Spiekermann K; Polzer H; Klaeger S; Kuster B; Böhmer FD; Fiebig HH; Krämer OH; Mahboobi S
Eur J Med Chem; 2020 May; 193():112232. PubMed ID: 32199135
[TBL] [Abstract][Full Text] [Related]
7. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
Zhang L; Lakkaniga NR; Bharate JB; Mcconnell N; Wang X; Kharbanda A; Leung YK; Frett B; Shah NP; Li HY
Eur J Med Chem; 2021 Dec; 225():113776. PubMed ID: 34479037
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors.
Lin XD; Yang HW; Ma S; Li WW; Zhang CH; Wang WJ; Xiang R; Li LL; Yang SY
Bioorg Med Chem Lett; 2015 Oct; 25(20):4534-8. PubMed ID: 26342867
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.
Long Y; Yu M; Ochnik AM; Karanjia JD; Basnet SK; Kebede AA; Kou L; Wang S
Eur J Med Chem; 2021 Mar; 213():113215. PubMed ID: 33516985
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML.
Nemes Z; Takács-Novák K; Völgyi G; Valko K; Béni S; Horváth Z; Szokol B; Breza N; Dobos J; Szántai-Kis C; Illyés E; Boros S; Kok RJ; Őrfi L
Bioorg Med Chem Lett; 2018 Aug; 28(14):2391-2398. PubMed ID: 29935772
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).
Ma F; Liu P; Lei M; Liu J; Wang H; Zhao S; Hu L
Eur J Med Chem; 2017 Feb; 127():72-86. PubMed ID: 28038328
[TBL] [Abstract][Full Text] [Related]
12. Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.
Yuan X; Chen Y; Zhang W; He J; Lei L; Tang M; Liu J; Li M; Dou C; Yang T; Yang L; Yang S; Wei Y; Peng A; Niu T; Xiang M; Ye H; Chen L
J Med Chem; 2019 Apr; 62(8):4158-4173. PubMed ID: 30939008
[TBL] [Abstract][Full Text] [Related]
13. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.
Baska F; Sipos A; Őrfi Z; Nemes Z; Dobos J; Szántai-Kis C; Szabó E; Szénási G; Dézsi L; Hamar P; Cserepes MT; Tóvári J; Garamvölgyi R; Krekó M; Őrfi L
Eur J Med Chem; 2019 Dec; 184():111710. PubMed ID: 31614258
[TBL] [Abstract][Full Text] [Related]
14. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.
Chen CT; Hsu JT; Lin WH; Lu CT; Yen SC; Hsu T; Huang YL; Song JS; Chen CH; Chou LH; Yen KJ; Chen CP; Kuo PC; Huang CL; Liu HE; Chao YS; Yeh TK; Jiaang WT
Eur J Med Chem; 2015 Jul; 100():151-61. PubMed ID: 26081023
[TBL] [Abstract][Full Text] [Related]
15. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
Xu B; Zhao Y; Wang X; Gong P; Ge W
Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G
Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079
[TBL] [Abstract][Full Text] [Related]
17. Design and Synthesis of 4-(Heterocyclic Substituted Amino)-1
Zhi Y; Wang Z; Yao C; Li B; Heng H; Cai J; Xiang L; Wang Y; Lu T; Lu S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731727
[TBL] [Abstract][Full Text] [Related]
18. Discovery and structure - activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors.
Chen Y; Bai G; Li Y; Ning Y; Cao S; Zhou J; Ding J; Zhang H; Xie H; Duan W
Bioorg Med Chem; 2021 Oct; 48():116422. PubMed ID: 34583130
[TBL] [Abstract][Full Text] [Related]
19. Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach.
Chang Hsu Y; Ke YY; Shiao HY; Lee CC; Lin WH; Chen CH; Yen KJ; Hsu JT; Chang C; Hsieh HP
ChemMedChem; 2014 May; 9(5):953-61. PubMed ID: 24665000
[TBL] [Abstract][Full Text] [Related]
20. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
[Next] [New Search]
